AbbVie
ABBV
#30
Rank
NZ$737.51 B
Marketcap
NZ$417.36
Share price
0.89%
Change (1 day)
25.30%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

Earnings for AbbVie (ABBV)

Earnings in 2026 (TTM): NZ$10.19 Billion

According to AbbVie's latest financial reports the company's current earnings are NZ$62.81 Billion. In 2025 the company made an earning of NZ$11.19 Billion, an increase over its 2024 earnings that were of NZ$6.30 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for AbbVie from 2011 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$10.19 B-8.9%
2025 NZ$11.19 B77.53%
2024 NZ$6.30 B-40.54%
2023 NZ$10.60 B-53.62%
2022 NZ$22.86 B3.76%
2021 NZ$22.03 B282.25%
2020 NZ$5.76 B-59.67%
2019 NZ$14.29 B62.13%
2018 NZ$8.81 B-32.74%
2017 NZ$13.10 B-1.99%
2016 NZ$13.37 B18.65%
2015 NZ$11.27 B180.5%
2014 NZ$4.01 B-55.57%
2013 NZ$9.04 B-6.86%
2012 NZ$9.71 B56.05%
2011 NZ$6.22 B

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
NZ$17.96 B 77.26%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$52.79 B 420.92%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$15.41 B 52.08%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$2.75 B-72.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$18.19 B 79.55%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$16.27 B 60.62%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$24.87 B 145.42%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$16.98 B 67.55%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$1.35 B-86.63%๐Ÿ‡บ๐Ÿ‡ธ USA